AXGN•benzinga•
Axogen, Inc. Announces Topline Results From Phase 3 RECON(SM) Study For Avance Nerve Graft; Co. Reports 'RECON achieved its Primary Endpoint'
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 4, 2022 by benzinga